Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: RS Group CEO invests, FRP Advisory CFO covers tax bill

(Sharecast News) - RS Group was on the list of director buys on Friday, after its chief executive officer purchased almost £0.12m worth of shares. The company said Simon Pryce picked up 16,400 shares on 27 July, in a single transaction on the London Stock Exchange.

Pryce paid 759.9285p for each share, valuing the transaction at a total of £124,628.27.

Elsewhere, FRP Advisory Group disclosed that on 28 July, its chief financial officer Gavin Jones exercised nil-cost options over 146,044 shares.

The options were satisfied using shares held in the company's Employee Benefit Trust.

Jones then sold 68,882 of the resulting shares at 118p apiece to satisfy personal income tax and national insurance liabilities arising on the option exercise.

Following the transactions, FRP said Jones beneficially held 145,343 of its shares, representing 0.06% of its issued share capital.

Reporting by Josh White for

Share this article

Related Sharecast Articles

Director dealings: Blue Coast raises stake in Everyman Media
(Sharecast News) - Everyman Media revealed on Thursday that Blue Coast had acquired 50,000 ordinary shares in the AIM-listed cinema group.
Director dealings: Angus Energy CEO ups stake
(Sharecast News) - Angus Energy revealed on Wednesday that chief executive Richard Herbert had acquired 5.0m ordinary shares in the AIM-listed onshore oil and gas development firm.
Director dealings: Abrdn CEO makes share sale
(Sharecast News) - Abrdn revealed on Monday that chief executive Stephen Bird had disposed of 29,942 ordinary shares in the FTSE 250-listed global investment company.
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.